Companies · Pharmaceuticals

Neuro-Innovators LLC

SEWICKLEY · Pharmaceuticals

Diligence memoA one-page analyst read on Neuro-Innovators LLC — recommendation, valuation, rhythm, risks.
$640K
Total raised · real
2
Rounds
5.4×
Latest step-up
Top 86%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Fri Jan 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Neuro-Innovators LLC looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.23× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
  • Within the normal band (123% of peer median) for its niche.
Quiet
  • Last raise 18 mo ago; this sector typically re-raises about every 13 months.
  • Slightly overdue versus sector cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Neuro-Innovators LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
3.5 yr record
Peak capital year was 2025 with $540K across 1 filings.
Market position
ahead of 15% of Pharmaceuticals peers
Capital scale is ahead of 15% of Pharmaceuticals peers; modeled value is above 4% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2025: $540K across 1 filings.
  • Largest single filing was $540K on 2025-01-10.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Neuro-Innovators LLC is one of 1613 Pharmaceuticals companies tracked from SEWICKLEY. By capital raised it ranks in the long tail (ahead of 15% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2021
Year incorporated
2025-01-10
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500K$1.0M$1.5M$2.0MPre-Seed · 2022-12-16 Raised $100K (real) Modeled valuation $1.1M (est)$100K$1.1MPre-Seed2022Pre-Seed · 2025-01-10 Raised $540K (real) Modeled valuation $1.8M (est)$540K$1.8MPre-Seed2025+$540KCumulative $640K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2022
Pre-Seed extension$540K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.8M
Base estimate est.
$303K
Conservative case
$5.1M
Upside case
$3.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $1.1M · 2022-12-162022Pre-Seed · modeled $1.8M · 2025-01-102025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
1.5 yr
Elapsed time used
1.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
25 mo
Avg between rounds
$309K/yr
Capital velocity
3.5 yr
On record since
2022
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$640K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.3× above median
This company$540K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.8M
Sector median$76.1M

Raised more than 15% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #7 of 19.

This companyCohort peer
$100K$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Fedora Pharmaceuticals Inc. · Pre-Seed Raised $1.1M · modeled $2.5M (est)PRG FlowChem, Inc. · Pre-Seed Raised $825K · modeled $2.5M (est)Adora Animal Health Corp · Pre-Seed Raised $1.0M · modeled $2.5M (est)ABLi Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $2.2M (est)NextEvo, Inc. · Pre-Seed Raised $600K · modeled $2.0M (est)Etheros Pharmaceuticals Corp. · Pre-Seed Raised $1.7M · modeled $1.9M (est)PridCor Therapeutics, LLC · Pre-Seed Raised $1.0M · modeled $1.8M (est)NOXX Therapeutics, Inc. · Pre-Seed Raised $1.5M · modeled $1.7M (est)Vogenx, Inc. · Pre-Seed Raised $750K · modeled $1.5M (est)Accretion Therapeutics, Inc. · Pre-Seed Raised $750K · modeled $1.3M (est)Macrotope, Inc. · Pre-Seed Raised $900K · modeled $1.1M (est)Neuro-Innovators LLC (this company) Raised $640K · modeled $1.8M (est)Neuro-Innovators LLC
CompanyStageRaised · realValue · estvs peer med.
Fedora Pharmaceuticals Inc.Pre-Seed$1.1M$2.5M1.72×
PRG FlowChem, Inc.Pre-Seed$825K$2.5M1.70×
Adora Animal Health CorpPre-Seed$1.0M$2.5M1.69×
ABLi Therapeutics, Inc.Pre-Seed$1.0M$2.2M1.53×
NextEvo, Inc.Pre-Seed$600K$2.0M1.36×
Etheros Pharmaceuticals Corp.Pre-Seed$1.7M$1.9M1.32×
Neuro-Innovators LLC this companyPre-Seed$640K$1.8M1.23×
PridCor Therapeutics, LLCPre-Seed$1.0M$1.8M1.22×
NOXX Therapeutics, Inc.Pre-Seed$1.5M$1.7M1.18×
Vogenx, Inc.Pre-Seed$750K$1.5M1.00×
Accretion Therapeutics, Inc.Pre-Seed$750K$1.3M0.91×
Macrotope, Inc.Pre-Seed$900K$1.1M0.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2022-12-16$556K$1.1M90%
Pre-Seed$540K2025-01-10$3.0M$1.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2022-12-16
    • First recorded raise — entered as Pre-Seed.
    • 2 investors on this round.
  2. Pre-Seed$540K2025-01-10
    • Raised again after 25 mo — slower than the ~13 mo sector norm.
    • Round 5.4× larger than the prior — scaling up.
    • 6 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~25mo cadence
$1.6M
Modeled next size est.range $1.1M$2.6M
5.4×
Last step-up
$309K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Blynn L. Schideler2022-12
John Howison Schroeder2022-12
Mark L. Cochran2022-12
Peter C. Doyle2022-12
Registry & provenance

Neuro-Innovators LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1960774
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
TF Tech Ventures, Inc.PharmaceuticalsPre-Seed$625K$8.3Msame sector · same stage
Telesis Therapeutics, LLCPharmaceuticalsPre-Seed$615K$13.4Msame sector · same stage
Goodsprout Co LLCPharmaceuticalsPre-Seed$600K$12.1Msame sector · same stage
NextEvo, Inc.PharmaceuticalsPre-Seed$600K$2.0Msame sector · same stage
Renavance Pharma, Inc.PharmaceuticalsPre-Seed$600K$4.7Msame sector · same stage
Eutropics Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$700K$2.1Msame sector · same stage
Lavior IncPharmaceuticalsPre-Seed$580K$13.3Msame sector · same stage
Gelesis Holdings, Inc.PharmaceuticalsPre-Seed$576K$7.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Neurovia, Inc.PharmaceuticalsSeries A$432.1M86%
NeuroRx, Inc.PharmaceuticalsSeries A$140.7M85%
Neurotez Inc.PharmaceuticalsSeed$76.1M85%
Neurodon CorpPharmaceuticalsPre-Seed$23.7M85%
Neurock Pharmaceuticals Inc.PharmaceuticalsSeries A$59.9M84%
Neurona Therapeutics, IncBiotechnologySeries D+$875.0M84%
Neuropro Therapeutics, Inc.BiotechnologySeries A$49.0M84%
Neuropharma, Inc.BiotechnologySeed$74.1M83%
Frequently asked
How much funding has Neuro-Innovators LLC raised?
Neuro-Innovators LLC has raised approximately $640K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Neuro-Innovators LLC's estimated valuation?
Provath's modeled valuation for Neuro-Innovators LLC is approximately $1.8M (modeled range $303K–$5.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Neuro-Innovators LLC at?
Neuro-Innovators LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Fri Jan 10.
What does Neuro-Innovators LLC do and where is it based?
Neuro-Innovators LLC operates in the Pharmaceuticals sector, based in SEWICKLEY.
Explore related

See where Neuro-Innovators LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Neuro-Innovators LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.